Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: Comment on the article by Erkan et al.

Arthritis and Rheumatism

Volumn 58, Issue 2, 2008, Pages 635-636

  Wahl, Denis ^a   Lecompte, Thomas ^a   Bounameaux, Henri ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOLIPIN ANTIBODY; HEPARIN; IBUPROFEN; LUPUS ANTICOAGULANT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; HIGH RISK PATIENT; HUMAN; LETTER; PNEUMONIA; PRIORITY JOURNAL; SMOKING; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; VENOUS THROMBOEMBOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; HUMANS; RISK FACTORS; THROMBOSIS;

EID: 39749112470     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23160     Document Type: Letter

References (5)

1. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007;56:2382-91.
2. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenasc inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
3. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
4. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000;160:2042-8.
5. Wahl DG, Guillemin F, De Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus: a meta-analysis. Lupus 1997;6:467-73.